J&J’s oral dengue drug shows promise in human challenge study

20 Oct 2023
firstwordpharma.com
Phase 2Clinical ResultsiRNAAACR
Johnson & Johnson’s Janssen Pharmaceutical unit announced Friday that the experimental oral drug JNJ-1802 induced antiviral activity against dengue in a Phase IIa study and was safe and well tolerated. The company noted that JNJ-1802 is the first antiviral to show such activity in humans during a clinical trial.
The human challenge study evaluated the antiviral activity of three dosing regimens of JNJ-1802 against an attenuated dengue 3 serotype (DENV-3) in healthy adults. All participants received daily doses of JNJ-1802 or placebo over 26 days, during which they were challenged with DENV-3 on day five.
According to Janssen, JNJ-1802 induced prophylactic antiviral activity against dengue, with a dose-dependent effect on the detectability of DENV-3 RNA and time to first onset of detectable DENV-3 RNA compared to placebo. The results were presented at the American Society of Tropical Medicine & Hygiene (ASTMH) annual meeting.
JNJ-1802 is now being investigated in a community-based field study to establish efficacy against circulating dengue serotypes in a real-world setting. The trial sites are in countries including Philippines, Thailand, Peru, Brazil and Colombia.
More to come.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.